Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Jun 1;35(4):187-195.
doi: 10.1097/MBC.0000000000001300. Epub 2024 Apr 18.

Aspirin versus low-molecular-weight heparin for thromboprophylaxis after orthopaedic surgery: a systematic review and meta-analysis

Haichao Wu  1 , Long Zhou, Qiang Wang, Tao Wang, Siyuan Liang
Affiliations
Meta-Analysis

Aspirin versus low-molecular-weight heparin for thromboprophylaxis after orthopaedic surgery: a systematic review and meta-analysis

Haichao Wu et al. Blood Coagul Fibrinolysis. .

Abstract

The article aimed to compare the efficiency and safety of aspirin with low-molecular-weight heparin (LMWH) for thromboprophylaxis in orthopaedic surgery patients. According to the inclusion and exclusion criteria, PubMed, Embase and Cochrane Library database were searched for studies comparing aspirin and LMWH in venous thromboembolism (VTE) prophylaxis until 25 April 2023. The outcome measures included deep venous thrombosis(DVT)/Pulmonary embolism(PE) events, major bleeding events, wound complications, wound infection and death. Six studies met the requirements of our meta-analysis, including 12 470 patients in the aspirin group and 10 857 patients in the LMWH group. The meta-analysis showed that results showed that LMWH was superior to aspirin in preventing VTE events (odds ratio (OR) 1.44, 95% CI 1.24-1.68, P < 0.00001), whereas there was no significant difference between them in bleeding events (OR 0.95, 95% CI 0.86-1.05, P = 0.33), wound complication (OR 0.58, 95% CI 0.28-1.17, P = 0.13), wound infection (OR 1.12, 95% CI 0.86-1.47, P = 0.39) and mortality (OR 1.04, 95% CI 0.70-1.55, P = 0.83). In addition, subgroup analysis showed that compared with aspirin, LMWH was more likely to reduce the incidence of DVT events in orthopaedic surgery patients (OR 1.59, 95% CI 1.33-1.91, P < 0.00001), whereas there was no advantage in reducing the incidence of PE events (OR 1.22, 95% CI 0.62-2.40, P = 0.56). Despite the similar safety profiles, this meta-analysis showed that LMWH was significantly superior to aspirin in thromboprophylaxis after orthopaedic surgery. LMWH was still the first-line drug for thrombosis prevention in patients who underwent major orthopaedic surgeries.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Fig. 1
Fig. 1
Preferred reporting items for systematic reviews and meta-analyses flow chart for article selection.
Fig. 2
Fig. 2
(a) Forest plot of the result comparing aspirin versus low-molecular-weight heparin for venous thromboembolism events. (b) Forest plot of the result comparing aspirin versus low-molecular-weight heparin (LMWH) for DVT events. (c) Forest plot of the result comparing aspirin versus LMWH for PE events. CI, confidence intervals; DVT, deep venous thrombosis; Fixed, a Fixed effects model; M–H, Mantel–Haenszel test; PE, Pulmonary embolism; Random, a random effects model.
Fig. 3
Fig. 3
Forest plot of the result comparing aspirin versus low-molecular-weight heparin for major bleeding events. CI, confidence intervals; Fixed, a Fixed effects model; M–H, Mantel–Haenszel test.
Fig. 4
Fig. 4
Forest plot of the result comparing aspirin versus low-molecular-weight heparin for wound complications. CI, confidence intervals; Fixed, a Fixed effects model; M–H, Mantel–Haenszel test.
Fig. 5
Fig. 5
Forest plot of the result comparing aspirin versus low-molecular-weight heparin for wound infection. CI, confidence intervals; M–H, Mantel–Haenszel test; Random, a random effects model.
Fig. 6
Fig. 6
Forest plot of the result comparing aspirin versus low-molecular-weight heparin for death. CI, confidence intervals; Fixed, a Fixed effects model; M–H, Mantel–Haenszel test.
Fig. 7
Fig. 7
Quality assessment of the included studies.
See this image and copyright information in PMC

References

    1. Majima T, Oshima Y. Venous thromboembolism in major orthopedic surgery. J Nippon Med School 2021; 88:268–272. - PubMed
    1. Memtsoudis SG, Pumberger M, Ma Y, Chiu YL, Fritsch G, Gerner P, et al. . Epidemiology and risk factors for perioperative mortality after total hip and knee arthroplasty. J Orthopaed Res 2012; 30:1811–1821. - PMC - PubMed
    1. Simon SJ, Patell R, Zwicker JI, Kazi DS, Hollenbeck BL. Venous Thromboembolism in Total Hip and Total Knee Arthroplasty. JAMA Netw Open 2023; 6:e2345883. - PMC - PubMed
    1. Kinov P, Tanchev PP, Ellis M, Volpin G. Antithrombotic prophylaxis in major orthopaedic surgery: an historical overview and update of current recommendations. Int Orthopaed 2014; 38:169–175. - PMC - PubMed
    1. Stewart DW, Freshour JE. Aspirin for the prophylaxis of venous thromboembolic events in orthopedic surgery patients: a comparison of the AAOS and ACCP guidelines with review of the evidence. Ann Pharmacother 2013; 47:63–74. - PubMed

MeSH terms